



Press Release

Friday, September 30, 2011



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

ONCOLOGY APPROVALS GAIN MOMENTUM WITH TWO MORE USFDA APPROVALS

APPROVAL FOR PACLITAXEL INJECTION AND TENTATIVE APPROVAL FOR OXALIPLATIN INJECTION

Paclitaxel to be launched through Pfizer immediately

September 30, 2011 Bangalore: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for Paclitaxel Injection USP, 6 mg/ ML packaged in 30 mg/ mL, 100 mg/16.7 mL and 300 mg/ 50 ML multiple dose vials.


Paclitaxel is among the products in the drug shortage list of the American Society of Health-System Pharmacists and the US FDA. According to IMS data, the US market for generic Paclitaxel approximated USD 46 Million. The Company will launch the product immediately.

The Company also received tentative approval for Oxaliplatin Injection which according to IMS data has a US market of approximately USD 1.4 Billion. While other generic Companies approved for this product are expected to launch the product in August 2012, Strides will issue further updates on this product in April 2012.

Paclitaxel and Oxaliplatin are part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market.

About Paclitaxel:

Paclitaxel, a Chemotherapy drug to be used alone or with other drugs to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma.



About Oxaliplatin:

Oxaliplatin is a chemotherapy drug used to treat advanced cancer of the colon and rectum. It is used in combination with other medications to slow or stop cancer cell growth.

About Agila Specialties

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Ajay Singh – 080 6784 0813 Mr. Kannan N - +91 98450 54745 (Investors)	Hiba Kunil +91 98807 26372 hiba@corvoshandwick.co.in

